NCT00714688
A Study to Evaluate Effectiveness and Safety of Prolonged Release OROS Methylphenidate in Adults With Attention Deficit Hyperactivity Disorder
See it on ClinicalTrials.gov ↗279 people
47.7%
52.3%
133 womenmiddle line = equal numbers146 men
- Phase
- PHASE3
- Paid for by
- Janssen-Cilag International NV
- Finished
- 2009-04
- Health conditions
- Attention Deficit/ Hyperactivity Disorder
- Who could join
- Anyone
- Ages
- 18 Years – 65 Years
- Average age
- mean 35.7 years
- Age 65+
- 0%
- Weight (BMI)
- Not reported
- Pregnancy recorded
- Not reported
- Menopause recorded
- Not reported
- Results shown by sex
- Not split by sex
- Race
- Not reported
Women left out
- No mental health conditions
Women with depression, bipolar disorder or other mental health conditions were turned away.
“Any clinically unstable psychiatric condition including, but not limited to the following: acute mood disorder, bipolar disorder, acute obsessive-compulsive disorder (OCD), anti-social personality disorder, borderline personality disorder.”
Study titles and rules are shown in their original English.